JP Morgan Maintains Overweight on Ionis Pharmaceuticals, Lowers Price Target to $70
Benzinga Newsdesk 1 month ago
Analyst RatingsNewsPrice Target
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.
JP Morgan analyst Jessica Fye maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Overweight and lowers the price target from $76 to $70.